drugset / Trial / NCT00214604

Type III Dysbetalipoproteinemia

NCT00214604

Phase 3 Completed 30 enrolled AstraZeneca
RandomizedCrossoverDouble-blindTreatment

Summary

Evaluation of the efficacy of rosuvastatin 10mg, rosuvastatin 20mg and pravastatin 40mg in subjects with dysbetalipoproteinemia.

Timeline

Start
2005-02
Primary completion
2007-02
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Pravastatin Small molecule 40 mg
Subject Rosuvastatin Small molecule 10 mg
Subject Rosuvastatin Small molecule 20 mg